GNH USA

Europe — EMA

Nitisinona Dipharma (Nitisinone)

GNH USA supplies Nitisinona Dipharma (Nitisinone), a tyrosine metabolism inhibitor for hereditary tyrosinemia type I treatment. Request a quote for supply.

Nitisinone

Request sourcing

1
Pack/s

What is Nitisinone?

Nitisinone, the active ingredient in Nitisinona Dipharma, is a Tyrosine metabolism inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of hereditary tyrosinemia type I in patients requiring metabolic control.

GNH USA supplies Nitisinona Dipharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Nitisinone used for?

Nitisinone acts on the tyrosine catabolic pathway and is used primarily for hereditary tyrosinemia type I.

Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites and improves liver function. Prevention of hepatic complications: helps maintain liver health and delays the need for transplantation in affected patients.

What are the side effects of Nitisinone?

Nitisinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Nausea - Vomiting - Abdominal pain - Fatigue - Skin rash

Serious or Rare Side Effects: - Elevated liver enzymes or hepatic failure - Neutropenia or other blood dyscrasias - Peripheral neuropathy - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Anaphylactic reactions - Acute renal impairment

What precautions apply to Nitisinone?

Patients receiving Nitisinona Dipharma should be monitored for safety and efficacy. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Renal function assessment: evaluate creatinine and electrolytes regularly. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Concomitant HPPD inhibitors: avoid co‑administration to prevent additive toxicity. - Drug-specific warnings: educate patients about signs of severe skin reactions and hepatic injury. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

What does Nitisinone interact with?

Nitisinona Dipharma can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: may increase INR and bleeding risk. - Other HPPD inhibitors: additive inhibition of tyrosine catabolism.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., phenytoin, sulfonylureas): possible altered plasma levels. - NSAIDs: may increase risk of renal impairment. - Antacids containing aluminum or magnesium: may affect absorption of oral Nitisinone.

Frequently asked questions

What is Nitisinona Dipharma used for?+
Nitisinona Dipharma contains nitisinone, which is prescribed to manage hereditary tyrosinemia type I. The drug works by preventing the buildup of toxic metabolites that can damage the liver and kidneys, helping to control disease progression in affected individuals.
How does nitisinone work in the body?+
Nitisinone blocks the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. By inhibiting this step, it stops the formation of harmful downstream compounds such as fumarylacetoacetate, thereby reducing liver and kidney toxicity associated with the disorder.
What is the usual dose of Nitisinona Dipharma?+
The specific dose of Nitisinona Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory results. Dosing regimens are individualized and should follow the clinician’s instructions.
Is Nitisinona Dipharma safe during pregnancy or breastfeeding?+
Safety data for nitisinone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.
How do I order Nitisinona Dipharma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Nitisinona Dipharma compare with other treatments for hereditary tyrosinemia type I?+
Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, whereas alternative options such as liver transplantation address end‑stage disease. Nitisinone offers a non‑surgical approach that can delay or prevent the need for transplantation when started early.
What are the storage requirements for Nitisinona Dipharma?+
Store Nitisinona Dipharma at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat, and direct sunlight to maintain stability and potency.
How is Nitisinona Dipharma administered?+
Nitisinona Dipharma is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule should follow the healthcare professional’s guidance.
What are the most serious risks associated with Nitisinona Dipharma?+
Serious risks include hepatic failure, severe skin reactions such as Stevens‑Johnson syndrome, neutropenia, and peripheral neuropathy. Patients should be monitored regularly for liver function, blood counts, and any signs of allergic or dermatologic reactions.
Who should not use Nitisinona Dipharma?+
Nitisinona Dipharma is contraindicated in patients with known hypersensitivity to nitisinone or any excipients, and in those with severe hepatic impairment where the drug’s metabolism could be compromised. Clinicians should evaluate each patient’s medical history before prescribing.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nitisinone
Route
Oral Use
Manufacturer
Dipharma Arzneimittel Gmbh
Origin
EU

Related products

Nitisinone 2 mg/1

Nitisinone 2 mg/1

Nitisinone · 2 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 5 mg/1

Nitisinone 5 mg/1

Nitisinone · 5 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 10 mg/1

Nitisinone 10 mg/1

Nitisinone · 10 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Mdk-Nitisinone 2 mg

Mdk-Nitisinone 2 mg

Nitisinone · 2 MG

Mdk-Nitisinone
CAPSULE
MENDELIKABS INC
CANADA